Production of a chimeric porcine reproductive and respiratory syndrome virus (PRRSV)-2 vaccine using a lab-scale packed-bed bioreactor CelCradle
© 2023. The Author(s)..
BACKGROUND: We developed a MARC-145 cell culture and porcine reproductive and respiratory syndrome (PRRS) vaccine production using a novel CelCradle bioreactor. CelCradle is a packed-bed bioreactor capable of both batch and perfusion culture, and the operating parameters are easy to optimize.
RESULTS: In this study, CelCradle reached a maximum cell density of 8.94 × 105 cells/mL at 5 days post-seeding when seeded at 8.60 × 104 cells/mL (doubling time = 35.52 h). Inoculation of PRRS vaccine candidate, K418DM1.1, was performed at a multiplicity of infection (MOI) of 0.01 at 5 days post-seeding, which resulted in a high viral titer of 2.04 × 108 TCID50/mL and total viral load of 1.02 × 1011 TCID50/500 mL at 2 days post-infection (dpi). The multilayer cultivation system, BioFactory culture, yielded a higher doubling time (37.14 h) and lower viral titer (i.e., 8.15 × 107 TCID50/mL) compared to the CelCradle culture. Thus, the culture medium productivity of the CelCradle culture was 2-fold higher than that of the BioFactory culture. In the animal experiment, the CelCradle-produced vaccine induced high levels of neutralizing antibodies and effectively protected pigs against homologous challenge, as shown by the significantly lower levels of viremia at 1- and 7-days post-challenge (dpc) compared to the non-vaccinated pigs.
CONCLUSIONS: Overall, this study demonstrates that the CelCradle system is an economical platform for PRRS vaccine production.
| Errataetall: |
ErratumIn: BMC Vet Res. 2023 Aug 9;19(1):115. - PMID 37559121 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
BMC veterinary research - 19(2023), 1 vom: 02. Aug., Seite 105 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Choi, Hwi-Yeon [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Viral |
|---|
| Anmerkungen: |
Date Completed 03.08.2023 Date Revised 23.11.2023 published: Electronic ErratumIn: BMC Vet Res. 2023 Aug 9;19(1):115. - PMID 37559121 Citation Status MEDLINE |
|---|
| doi: |
10.1186/s12917-023-03659-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360281648 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360281648 | ||
| 003 | DE-627 | ||
| 005 | 20231226082700.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12917-023-03659-4 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1200.xml |
| 035 | |a (DE-627)NLM360281648 | ||
| 035 | |a (NLM)37528389 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Choi, Hwi-Yeon |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Production of a chimeric porcine reproductive and respiratory syndrome virus (PRRSV)-2 vaccine using a lab-scale packed-bed bioreactor CelCradle |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.08.2023 | ||
| 500 | |a Date Revised 23.11.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a ErratumIn: BMC Vet Res. 2023 Aug 9;19(1):115. - PMID 37559121 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a BACKGROUND: We developed a MARC-145 cell culture and porcine reproductive and respiratory syndrome (PRRS) vaccine production using a novel CelCradle bioreactor. CelCradle is a packed-bed bioreactor capable of both batch and perfusion culture, and the operating parameters are easy to optimize | ||
| 520 | |a RESULTS: In this study, CelCradle reached a maximum cell density of 8.94 × 105 cells/mL at 5 days post-seeding when seeded at 8.60 × 104 cells/mL (doubling time = 35.52 h). Inoculation of PRRS vaccine candidate, K418DM1.1, was performed at a multiplicity of infection (MOI) of 0.01 at 5 days post-seeding, which resulted in a high viral titer of 2.04 × 108 TCID50/mL and total viral load of 1.02 × 1011 TCID50/500 mL at 2 days post-infection (dpi). The multilayer cultivation system, BioFactory culture, yielded a higher doubling time (37.14 h) and lower viral titer (i.e., 8.15 × 107 TCID50/mL) compared to the CelCradle culture. Thus, the culture medium productivity of the CelCradle culture was 2-fold higher than that of the BioFactory culture. In the animal experiment, the CelCradle-produced vaccine induced high levels of neutralizing antibodies and effectively protected pigs against homologous challenge, as shown by the significantly lower levels of viremia at 1- and 7-days post-challenge (dpc) compared to the non-vaccinated pigs | ||
| 520 | |a CONCLUSIONS: Overall, this study demonstrates that the CelCradle system is an economical platform for PRRS vaccine production | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Bioreactor | |
| 650 | 4 | |a CelCradle | |
| 650 | 4 | |a Packed Bed | |
| 650 | 4 | |a Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) | |
| 650 | 4 | |a Vaccine efficacy | |
| 650 | 4 | |a Vaccine production | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Viral Vaccines |2 NLM | |
| 650 | 7 | |a Vaccines, Attenuated |2 NLM | |
| 700 | 1 | |a Choi, Jong-Chul |e verfasserin |4 aut | |
| 700 | 1 | |a Kang, Yeong-Lim |e verfasserin |4 aut | |
| 700 | 1 | |a Ahn, So-Hyeun |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Sang-Won |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Seung-Yong |e verfasserin |4 aut | |
| 700 | 1 | |a Song, Chang-Seon |e verfasserin |4 aut | |
| 700 | 1 | |a Choi, In-Soo |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Joong-Bok |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMC veterinary research |d 2005 |g 19(2023), 1 vom: 02. Aug., Seite 105 |w (DE-627)NLM156806703 |x 1746-6148 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2023 |g number:1 |g day:02 |g month:08 |g pages:105 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12917-023-03659-4 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2023 |e 1 |b 02 |c 08 |h 105 | ||